Po­laris’ Amir Nashat pulls to­geth­er a $60M launch round to back the birth of a new biotech build­ing a drug de­vel­op­ment plat­form from scratch

Po­laris Part­ners man­ag­ing part­ner Amir Nashat has be­come a stu­dent of the role that bio­mol­e­c­u­lar con­den­sates play in shut­ting down or ac­ti­vat­ing pro­teins. And he’s con­vinced that he’s found a door that opens on a long path­way to a new drug plat­form.

So con­vinced that he’s gath­ered a glob­al syn­di­cate to­geth­er and pack­aged a $60 mil­lion launch round to back the 15 staffers at Dew­point Ther­a­peu­tics who have been as­sem­bled to start craft­ing a pipeline of new drugs from their work.

Richard Young

Nashat and his col­leagues know it’s ear­ly, but they’ve grown in­creas­ing­ly ex­cit­ed about the steady stream of pa­pers be­ing pub­lished on con­den­sates — or­ganelles in cells with­out mem­branes — and the role they play in dis­ease. Some of those pa­pers are from com­pa­ny founders who will now help guide Dew­point to the clin­ic, in­clud­ing the White­head In­sti­tute’s Richard Young and An­tho­ny Hy­man of the Max Planck In­sti­tute.

That sci­en­tif­ic team — backed by a promi­nent group of sci­en­tif­ic ad­vis­ers that in­cludes the ubiq­ui­tous Bob Langer at MIT — in turn helped bring in Po­laris’ syn­di­cate part­ners: Sam­sara Bio­Cap­i­tal, 6 Di­men­sions Cap­i­tal, EcoR1 Cap­i­tal, Alexan­dria Ven­ture In­vest­ments, and Leaps by Bay­er.

An­tho­ny Hy­man

“Neu­rode­gen­er­a­tion seems to be con­den­sates gone wrong,” says Nashat, who’s tak­en the CEO spot. And fo­cus­ing on mol­e­cules and reagents that can change the move­ment of a pro­tein in or out of con­den­sates looks like a promis­ing ap­proach to reg­u­lat­ing pro­tein be­hav­ior — stop­ping or en­hanc­ing the process as an av­enue to new drug de­vel­op­ment where all else has failed.

Adds Nashat: “It was a wide open can­vas.”

But not one that’s easy to paint just now. The Cam­bridge, MA-based Dew­point team, which will now dou­ble in size over the next year, doesn’t have a late-stage pre­clin­i­cal pro­gram it can shove in­to the clin­ic. The biotech is in­vest­ing in neu­rode­gen­er­a­tion, can­cer, car­dio­vas­cu­lar and oth­er ar­eas for a plat­form that could, even­tu­al­ly, have ex­ten­sive ap­pli­ca­tions. But asked about a time­line to proof-of-con­cept da­ta, Nashat frankly es­ti­mates that it will take 4-5 years to birth some hard hu­man da­ta. The mon­ey should get them through 3 years and a con­sid­er­able de-risk­ing ap­proach to their pre­clin­i­cal ef­forts

The CSO is Mark Mur­cko, an ex­pe­ri­enced and well known start­up play­er.

Mark Mur­cko

“When I think about new com­pa­nies a lot of it is about tim­ing; is it too soon or too late?” Mur­cko notes en­thu­si­as­ti­cal­ly in our in­ter­view. “Is there enough in­for­ma­tion avail­able to make you think you can take that and use it to­ward new drugs? Five years ago it was too ear­ly, too nascent.”

Now, Mur­cko adds, seems like a great time to give this a go.


Im­age: Amir Nashat. WMIF via YOUTUBE

Scoop: Boehringer qui­et­ly shut­ters a PhII for one of its top drugs — now un­der re­view

Boehringer Ingelheim has quietly shut down a small Phase II study for one of its lead drugs.

The private pharma player confirmed to Endpoints News that it had shuttered a study testing spesolimab as a therapy for Crohn’s patients suffering from bowel obstructions.

A spokesperson for the company tells Endpoints:

Taking into consideration the current therapeutic landscape and ongoing clinical development programs, Boehringer Ingelheim decided to discontinue our program in Crohn’s disease. It is important to note that this decision is not based on any safety findings in the clinical trials.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Vas Narasimhan (Photographer: Jason Alden/Bloomberg via Getty Images)

No­var­tis de­tails plans to axe 8,000 staffers as Narasimhan be­gins sec­ond phase of a glob­al re­org

We now know the number of jobs coming under the axe at Novartis, and it isn’t small.

The pharma giant is confirming a report from Swiss newspaper Tages-Anzeiger that it is chopping 8,000 jobs out of its 108,000 global staffers. A large segment will hit right at company headquarters in Basel, as CEO Vas Narasimhan axes some 1,400 of a little more than 11,000  jobs in Switzerland.

The first phase of the work is almost done, the company says in a statement to Endpoints News. Now it’s on to phase two. In the statement, Novartis says:

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,500+ biopharma pros reading Endpoints daily — and it's free.

Lina Gugucheva, NewAmsterdam Pharma CBO

Phar­ma group bets up to $1B-plus on the PhI­II res­ur­rec­tion of a once dead-and-buried LDL drug

Close to 5 years after then-Amgen R&D chief Sean Harper tamped the last spade of dirt on the last broadly focused CETP cholesterol drug — burying their $300 million upfront and the few remaining hopes for the class with it — the therapy has been fully resurrected. And today, the NewAmsterdam Pharma crew that did the Lazarus treatment on obicetrapib is taking another big step on the comeback trail with a €1 billion-plus regional licensing deal, complete with close to $150 million in upfront cash.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,500+ biopharma pros reading Endpoints daily — and it's free.

How pre­pared is bio­phar­ma for the cy­ber dooms­day?

One of the largest cyberattacks in history happened on a Friday, Eric Perakslis distinctly remembers.

Perakslis, who was head of Takeda’s R&D Data Sciences Institute and visiting faculty at Harvard Medical School at the time, had spent that morning completing a review on cybersecurity for the British Medical Journal. Moments after he turned it in, he heard back from the editor: “Have you heard what’s going on right now?”

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Pearl Huang, Dunad Therapeutics CEO (Ken Richardson, PR Newswire)

Long­time biotech leader Pearl Huang takes the reins as CEO of No­var­tis-backed up­start

It has only been a few months since Pearl Huang exited the top seat at Cygnal Therapeutics, but now she’s back at the helm of another biotech.

After taking a few months off — passing an exam in that time to get her captain’s license from the US Coast Guard — she’s been named CEO of Dunad Therapeutics, a biotech focused on developing a small molecule covalent therapies that was founded in 2020. Huang told Endpoints News that two factors attracted her to going back to the c-suite: the company’s technology and its co-founders.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,500+ biopharma pros reading Endpoints daily — and it's free.

(AP Photo/Gemunu Amarasinghe)

Some phar­ma com­pa­nies promise to cov­er abor­tion-re­lat­ed trav­el costs — while oth­ers won't go that far yet

As the US Department of Health and Human Services promises to support the millions of women who would now need to cross state lines to receive a legal abortion, a handful of pharma companies have said they will pick up employees’ travel expenses.

GSK, Sanofi, Johnson & Johnson, BeiGene, Alnylam and Gilead have all committed to covering abortion-related travel expenses just four days after the Supreme Court overturned Roe v. Wade and revoked women’s constitutional right to an abortion.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,500+ biopharma pros reading Endpoints daily — and it's free.

Aurobindo Pharma co-founders P. V. Ram Prasad Reddy (L) and K. Nityananda Reddy

Au­robindo Phar­ma re­ceives warn­ing let­ter from In­di­a's SEC fol­low­ing more FDA ques­tion marks

Indian-based generics manufacturer Aurobindo Pharma has been in the crosshairs of the FDA for several years now, but the company is also attracting attention from regulators within the subcontinent.

According to the Indian business news site Business Standard, a warning letter was sent to the company from the Securities Exchange Board of India, or SEBI.

The letter is related to disclosures made by the company on an ongoing FDA audit of the company’s Unit-1 API facility in Hyderabad, India as well as observations made by the US regulator between 2019 and 2022.

New Charles River Laboratories High Quality (HQ) Plasmid DNA Centre of Excellence at Bruntwood SciTech’s Alderley Park in Cheshire, United Kingdom. (Charles River)

Charles Riv­er Lab­o­ra­to­ries to start cell and gene ther­a­py man­u­fac­tur­ing at UK site in Sep­tem­ber

While Massachusetts-based Charles River Laboratories has been on an acquisition spree, they are not against planting their flag. The latest move by the company sees them crossing the pond to establish a manufacturing site in the UK.

The company on Tuesday opened its cell and gene therapy manufacturing center at Bruntwood SciTech’s Alderley Park in Cheshire, United Kingdom. The expansion follows Charles River’s acquisition of Cognate BioServices and Cobra Biologics in 2021 for $875 million. Cognate is a plasmid DNA, viral vector and cell therapy CDMO.

Bristol Myers Squibb (Alamy)

CVS re­sumes cov­er­age of block­buster blood thin­ner af­ter price drop fol­lows Jan­u­ary ex­clu­sion

Following some backlash from the American College of Cardiology and patients, Bristol Myers Squibb and Pfizer lowered the price of their blockbuster blood thinner Eliquis, thus ensuring that CVS Caremark would cover the drug after 6 months of it being off the major PBM’s formulary.

“Because we secured lower net costs for patients from negotiations with the drug manufacturer, Eliquis will be added back to our template formularies for the commercial segment effective July 1, 2022, and patient choices will be expanded,” CVS Health said in an emailed statement. “Anti-coagulant therapies are among the non-specialty products where we are seeing the fastest cost increases from drug manufacturers and we will continue to push back on unwarranted price increases.”